# Immpact Bio USA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immpact-bio-usa

- Industry: Biotechnology
- Headquarters: Camarillo, US
- Website: www.immpact-bio.com
- Total disclosed funding: $115M
- Latest round: Series B (Jan 14, 2022)
- Investors on record: 12

## About

Immpact Bio USA Inc. is a biotechnology company focused on developing innovative CAR T cell therapies to tackle significant challenges in oncology and autoimmune diseases.Founded in 2017 and headquartered in Camarillo, US, Immpact Bio USA Inc. specializes in creating advanced CAR T cell therapies. The company was formed to leverage cutting-edge technology in addressing difficult medical conditions. Recently, on October 24, 2024, Immpact Bio was acquired by Lyell Immunopharma, Inc. for USD 30.00 mn in cash, strengthening Lyell's cancer treatment pipeline. The company has participated in 3 investment deals, all contributing to its focus on innovative therapies.ImmPACT Bio specializes in the development of innovative bispecific Chimeric Antigen Receptor (CAR) T cell therapies aimed at addressing significant challenges in oncology and autoimmune diseases. Their core products leverage cutting-edge iCAR technology, designed to selectively target and eliminate cancer cells while preserving normal tissue, with applications across all solid tumors. The company’s product offerings include advanced CAR T cell platforms that focus on preventing antigen escape and overcoming the immunosuppressive microenvironment commonly found in cancers. ImmPACT Bio's therapies are primarily aimed at healthcare providers, clinical research institutions, and pharmaceutical partners involved in treating patients with grievous diseases, particularly in areas such as systemic lupus erythematosus (SLE) and various types of cancers. Their products are targeted towards markets in North America, Europe, and parts of Asia where there is a growing need for advanced cancer therapies and solutions for autoimmune conditions.ImmPACT Bio generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions, focused on the commercialization of their advanced CAR T cell therapies. The structure of transactions typically involves joint development agreements and licensing arrangements, allowing partners to leverage ImmPACT Bio's proprietary technologies in exchange for upfront payments and milestone payments as products advance through clinical trials and regulatory approvals. Additionally, revenue may be driven by revenue-sharing models post-commercialization, where partners distribute the therapies to healthcare providers and institutions. The flagship products, including those targeting systemic lupus erythematosus and various cancers, are central to these transactions, which may include specific pricing tiers based on the scale and scope of the partnership.The recent acquisition of Immpact Bio by Lyell Immunopharma on October 24, 2024, for USD 30.00 mn will bolster Lyell's focus on next-generation CAR T-cell therapies, particularly IMPT-314 that addresses cancer treatments. This strategic move will likely expand Immpact Bio's product offerings and market reach, reinforcing their commitment to innovative cancer therapies.

## Funding rounds

- Series B, Jan 14, 2022, $111M — OrbiMed Advisors, Novartis Venture Fund, Foresite Capital, Decheng Capital, VenBio, Bukwang Pharmaceutical Co., Ltd., RM Global Partners, Surveyor Capital
- Series A, Jul 16, 2020, $3.8M — OrbiMed Advisors, Novartis Venture Fund, Johnson & Johnson Innovation, Takeda Ventures, Bukwang Pharmaceutical Co., Ltd., RM Global Partners, JVC Investment Partners, Hayan Health Networks

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- Bukwang Pharmaceutical Co., Ltd. — Series A, Series B
- RM Global Partners (https://capitalatlas.ai/funds/rm-global-partners) — Series A, Series B
- JVC Investment Partners (https://capitalatlas.ai/funds/jvc-investment-partners) — Series A
- Hayan Health Networks (https://capitalatlas.ai/funds/hayan-health-networks) — Series A
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B
- Surveyor Capital — Series B